MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors - Top-Institutions - MDSpire

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • By

  • May 7, 2026

  • 4 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, New York

    Key Differentiators

    • Oncology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #3

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Oncology

Original Source(s)

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

  • by

  • May 7, 2026

Related Content

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review